Mary Miller - 05 Oct 2026 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Reporting relationship: Chief Legal Officer
Issuer ticker: ACRV
Reported as of: 05 Oct 2026
Net transaction value: -$585
SEC form: 4
Accepted by SEC: 07 Oct 2026, 17:02:25 UTC
Prior SEC filing: 20 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Adam D. Levy, Attorney-in-Fact

Key filing fact

Mary Miller filed Form 4 for Acrivon Therapeutics, Inc. (ACRV) on 07 Oct 2026.

Key facts

This page summarizes Mary Miller's Form 4 filing for Acrivon Therapeutics, Inc. (ACRV).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 07 Oct 2026, 17:02.

Change

Previous filing in this sequence was filed on 20 Aug 2026.
Current net transaction value: -$585.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001841088 Primary reporting owner

Miller Mary

Relationship: Chief Legal Officer
Address: C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN
Signature: /s/ Adam D. Levy, Attorney-in-Fact
Signature date: 07 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ACRV transaction

Common Stock

Sale

Transaction value: $585
Shares: -294
Change %: -0.36%
Price: $1.99
Shares after: 81,715
Date: 05 Oct 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Footnote F2

The price reported in Column 4 above reflects the weighted average price of 337 shares sold by a broker on October 5, 2026, to satisfy the payment of withholding tax liability of a group of employees of the Issuer, including the reporting person. The proceeds of all such sales were allocated to the employees, including the reporting person, on a pro rata basis.